SCI-FI MILESTONES · REFERENCE PROJECT

WAYFARER

Tracking the distance between science fiction and reality — from verified research to technologies humanity may one day build into its first true deep-space ship.

Scripps Research · July 2026

Autologous iPSC-derived dopamine neuron precursor transplantation

Presentation of 12-month interim clinical findings from a Phase 1/2a trial for Parkinson's disease, demonstrating the safety, feasibility, and biological activity of transplanting individualized dopamine neuron precursor cells.

PASSregenerative medicineHUMAN_TRIAL_RESULTconfidence: high

Search window: 2026-05-06 → 2026-09-02Record: 20260902_173642_regenerative-medicine.json

Why it matters

This event marks a significant transition in regenerative medicine from theoretical models to clinical reality, providing primary evidence that personalized, autologous stem cell-derived therapies can be safely and feasibly applied to complex neurodegenerative diseases in humans.

Verified claims

Interim 12-month clinical findings from the first Phase 1/2a trial for Parkinson's disease showed that eight patients with mild to moderate disease remained responsive to L-DOPA treatment.

patient_count: 8 patients

The transplantation of autologous induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells demonstrated safety and feasibility in the examined cohort.

Limitations

Small patient cohort (n=8)
Interim nature of findings (12-month follow-up)
Requirement for further dose optimization
Need for long-term monitoring of graft maturation and durability

Sources

Data Presented at ISSCR 2026 Highlight Progress Toward Personalized Stem Cell Therapy for Parkinson’s DiseaseISSCR · 2026-07-09 · primary